• SUBSCRIBE
    • Action Alerts PLUS
    • Real Money
    • Real Money Pro
    • Quant Ratings
    • Retirement Daily
    • Stocks Under $10
    • Trifecta Stocks
    • Top Stocks
    • Real Money Pro Portfolio
    • Chairman's Club
    • Compare All
  • JIM CRAMER
    • Action Alerts PLUS
    • Cramer's Blog
    • Cramer's Monthly Call
    • Jim Cramer's Best Stocks
    • Cramer's Articles
    • Mad Money
    • 25 Rules for Investing
    • 10 Commandments
  • INVESTING
    • Bitcoin
    • Cannabis
    • Cryptocurrency
    • ETFs
    • Earnings
    • Fixed Income
    • Funds
      • Bond Funds
      • Index Funds
      • Mutual Funds
    • Futures
    • Options
    • REITs
    • Stocks
      • Penny Stocks
      • Preferred Stocks
  • PERSONAL FINANCE
    • Credit Cards
    • Debt Management
    • Education
    • Employee Benefits
    • Insurance
      • Car Insurance
      • Disability Insurance
      • Health Insurance
      • Home Insurance
      • Life Insurance
    • Mortgages
    • Real Estate
    • Savings
    • Taxes
  • RETIREMENT
    • 401K
    • Estate Planning
    • IRAs
      • Roth IRAs
    • Social Security
  • TECHNOLOGY
    • Cybersecurity
  • MARKETS
    • Bankruptcy
    • Commodities
      • Gold
      • Oil
    • Corporate Governance
    • Currencies
    • Emerging Markets
    • IPOs
    • Mergers and Acquisitions
    • Rates and Bonds
      • Junk Bonds
      • Treasury Bonds
    • Regulation
  • HOW-TO
  • VIDEO
    • Audio
  • Courses
    • Personal Finance Essentials
    • Fundamentals of Investing
  • Terms Of Use
  • Privacy Policy
  • Advertise
  • Reprints
  • Customer Service
  • Data
  • Topic Archive
  • Subscriptions
  • Privacy Settings
Logo
  • JIM CRAMER
  • INVESTING
  • PERSONAL FINANCE
  • RETIREMENT
  • TECHNOLOGY
  • MARKETS
  • HOW-TO
  • VIDEO
  • COURSES
Login
Account
TheStreet

Log In

Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
Forgot your password?Don't have an account? Sign Up Here

Join Us

Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
Already have an account? Login here
  • Alerts
  • |
  • Newsletters
Logo
  • JIM CRAMER
  • INVESTING
  • PERSONAL FINANCE
  • RETIREMENT
  • TECHNOLOGY
  • MARKETS
  • HOW-TO
  • VIDEO
  • COURSES
Login
Account

Trade with Jim Cramer 14 Days Free

Join the Action Alerts PLUS Community today!

SUBSCRIBE NOW

LATEST NEWS

Gilead Sciences Names Roche's O'Day as CEO and Chairman
STOCKS

Will Gilead Sciences Stock Really Rally 33% From Here?

  • By Bret Kenwell
  • Jul 15, 2019 3:29 PM EDT
Gilead Sciences Names Roche's O'Day as CEO and Chairman
STOCKS

Gilead Boosts Investment in Inflammatory Specialist Galapagos by $5.1 Billion

  • By Martin Baccardax
  • Jul 15, 2019 9:40 AM EDT
Abiomed Shares Take Beating After Studies Question Heart Pump
STOCKS

Galapagos Soars After Rheumatoid Arthritis Drug Meets Primary Endpoint

  • By Alexander Nicoll
  • Mar 29, 2019 11:06 AM EDT
Vertex Pharma Jumps 14% After Rival Releases Poor Cystic Fibrosis Drug Results
STOCKS

Vertex Pharma jumps 14% after rival releases poor cystic fibrosis drug results

  • By Alexander Nicoll
  • Jun 29, 2018 3:27 PM EDT
Vertex Pharma (VRTX) Stock Lower on Q3 Miss
STOCKS

Vertex pharma moves next-generation cystic fibrosis drugs into new clinical trials

  • By Adam Feuerstein
  • Oct 25, 2016 5:03 PM EDT
Celgene Stock Falls Following Argus Downgrade
STOCKS

Celgene skips the placebo, fails drug development 101

  • By Adam Feuerstein
  • Oct 19, 2016 7:28 AM EDT
Duchenne Drug Developer (Not Sarepta) Hit With Lengthy FDA Delay
STOCKS

AstraZeneca, Gilead Drug License Deals Could Pinch AbbVie Growth

  • By Adam Feuerstein
  • Dec 17, 2015 8:48 AM EST
Vertex Pharma Jumps 14% After Rival Releases Poor Cystic Fibrosis Drug Results
STOCKS

Vertex to Test New Cystic Fibrosis Drugs, Seeking Broader, More Effective Treatments

  • By Adam Feuerstein
  • Oct 8, 2015 12:10 PM EDT
Pfizer's Poor Earnings Feed the Allergan Tie-Up Fire
STOCKS

Credit Suisse's 8 Pharmaceutical Stocks With 'Significant' Upside

  • By Laurie Kulikowski
  • Aug 28, 2015 12:58 PM EDT
Galapagos Receives a Rousing Welcome on Its First Day of Trading
STOCKS

Galapagos Receives a Rousing Welcome on Its First Day of Trading

  • By James Rubin
  • May 14, 2015 6:27 PM EDT
Galapagos Drug in Partnership With AbbVie Looks to Replace HUMIRA
VIDEO

Galapagos Drug in Partnership With AbbVie Looks to Replace HUMIRA

  • By Jill Malandrino
  • May 14, 2015 3:51 PM EDT
TheStreet
  • Terms Of Use
  • Privacy Policy
  • Advertise
  • Reprints
  • Customer Service
  • Data
  • Topic Archive
  • Subscriptions
© 2019 TheStreet, Inc. All rights reserved. Action Alerts PLUS is a registered trademark of TheStreet, Inc.